Conveying Risks of Harm in Alzheimer Disease by Amyloid Lowering.

This Viewpoint discusses how data gaps in published research impede clinicians’ ability to clearly discuss the risks and benefits of amyloid-lowering drugs for treating Alzheimer disease.